Related content

The economics of febrile neutropenia: implications for the use of colony-stimulating factors

By Lyman G.H.   Kuderer N.   Greene J.   Balducci L.  

European Journal of Cancer, Vol. 34, Iss. 12, 1998-11 ,pp. : 1857-1864

Elsevier

Access to resources Recommend Favorite

Colony-stimulating factors for chemotherapy-related febrile neutropenia are associated with improved prognosis in adult acute lymphoblastic leukemia

By            

Molecular and Clinical Oncology, Vol. 3, Iss. 3, 2015-01 ,pp. : 730-736

Science Publishers

Access to resources Recommend Favorite

Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy

By Yakushijin Yoshihiro   Shikata Hisaharu   Takaoka Ikue   Horikawa Tamami   Takeuchi Kazuhito   Yamanouchi Jun   Azuma Taichi   Narumi Hiroshi   Hato Takaaki   Yasukawa Masaki  

International Journal of Clinical Oncology, Vol. 16, Iss. 2, 2011-04 ,pp. : 118-124

Springer Publishing Company

Access to resources Recommend Favorite

Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients: A systematic review of the literature with meta-analysis

By Berghmans T.   Paesmans M.   Lafitte J.   Mascaux C.   Meert A.   Jacquy C.   Burniat A.   Steels E.   Vallot F.   Sculier J.  

Supportive Care in Cancer, Vol. 10, Iss. 3, 2002-04 ,pp. : 181-188

Springer Publishing Company

Access to resources Recommend Favorite

The safety of full-dose chemotherapy with secondary prophylactic granulocyte colony stimulating factor (G-CSF) following a prior cycle with febrile neutropenia

By Haim Nissim   Shulman Katerina   Goldberg Hadassah   Tsalic Medy  

Medical Oncology, Vol. 22, Iss. 3, 2005-09 ,pp. : 229-232

Humana Press, Inc

Access to resources Recommend Favorite